Non-compressible hemorrhage control is a big challenge in both civilian life and the
battlefield, causing a majority of deaths among all traumatic injury mortalities. Unexpected …

Hemorrhage is the leading cause of preventable death in combat trauma and the secondary
cause of death in civilian trauma. A significant number of deaths due to hemorrhage occur …

Background In response to the World Health Organization call for research on alternative
routes for tranexamic acid (TXA) administration in women with postpartum haemorrhage, we …

Tranexamic acid (TXA) is a potent antifibrinolytic with documented efficacy in reducing blood
loss and allogeneic red blood cell transfusion in several clinical settings. With a growing …

Objective: To review the efficacy and safety of a single dose of intravenous tranexamic acid
(TXA) given preoperatively. Summary Background Data: TXA is a synthetic antifibrinolytic …

The publication of the Clinical Randomization of an Antifibrinolytic in Significant
Hemorrhage-2 (CRASH-2) study and its intense dissemination prompted a renaissance for …

MYH9-related disease patients with mutations in the contractile protein nonmuscle myosin
heavy chain IIA display, among others, macrothrombocytopenia and a mild-to-moderate …

Tranexamic acid (TXA) is a widely used antifibrinolytic agent that has been used since the
1960's to reduce blood loss in various conditions. TXA is a lysine analogue that competes …

Abstract In the United States, trauma claims the lives of over 150,000 civilians each year. In
military settings, trauma and exsanguination result in 50% of combat related deaths. The …

Tranexamic acid (TXA) significantly reduces blood loss in a wide range of surgical
procedures and improves survival rates in obstetric and trauma patients with severe …